Millendo Therapeutics, Inc. announced the appointments of Tamara Joseph, JD, LLM, as General Counsel and Corporate Secretary and Ryan Zeidan, PhD, as Chief Development Officer. Ms. Joseph succeeds Jeffery M. Brinza who announced his retirement in March. Ms. Joseph joins Millendo with more than 20 years of leadership roles in multiple biotechnology companies, overseeing legal, compliance, public and government affairs, and risk management. She most recently served as General Counsel at Enzyvant Therapeutics and previously served as General Counsel at InVivo Therapeutics, Cubist Pharmaceuticals, Mayne Pharma, and Transkaryotic Therapies (TKT). Dr. Zeidan has served as Senior Vice President of Development at Millendo since joining the company in 2018. In this role he has overseen critical R&D functions including clinical operations, project management, CMC and regulatory affairs. Prior to Millendo, Dr. Zeidan was with Celgene, where he oversaw the development and advancement of two late-stage oncology assets to Phase 3 registration studies, and with Novartis Oncology, where he served as Executive Director, Global Strategy and Operations.